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Abstract
Small bowel transplantation (SBT) can be a life-saving medical procedure. However, these recipients experience high risk of bloodstream infections caused by Candida. This research aims to characterize the
SBT recipient gut microbiota over time following transplantation and investigate the epidemiology of
candidemia in seven pediatric patients. Candida species from the recipients’ ileum and bloodstream were
identified by internal transcribed spacer sequence and distinguished to strain by multilocus sequence
typing and randomly amplified polymorphic DNA. Antifungal susceptibility of bloodstream isolates was
determined against nine antifungals. Twenty-two ileostomy samples harbored at least one Candida species. Fungemia were caused by Candida parapsilosis, Candida albicans, Candida glabrata, Candida orthopsilosis and Candida pelliculosa. All but three bloodstream isolates showed susceptibility to all the
antifungals tested. One C. glabrata isolate showed multidrug resistance to itraconazole, amphotericin B
and posaconazole and intermediate resistance to caspofungin. Results are congruent with both endogenous (C. albicans, C. glabrata) and exogenous (C. parapsilosis) infections; results also suggest two patients
were infected by the same strain of C. parapsilosis. Continuing to work towards a better understanding of
sources of infection—particularly the exogenous sources—would lead to targeted prevention strategies.
Keywords: candidemia, fungemia, microbiota, mycobiota

1 Introduction

rate estimates of nearly 50%,4 especially in immunocompromised patients.
Solid organ transplant (SOT) recipients present a unique
combination of risk factors that may predispose them to
candidemia, including prolonged administration of immunosuppressive therapies, repeated courses of broad-spectrum antibiotics, hemodialysis, various surgical procedures
and presence of central venous catheters.5,6 SBT recipients
evince a higher incidence of allograft rejection than other
SOT recipients, due to the high immunogenicity of the bowel,
and therefore require more potent immunosuppression therapy.7 During episodes of allograft rejection or breach of the

Candida species colonize the gastrointestinal and reproductive tract and skin of most individuals and are among
the most common causes of hospital-acquired bloodstream
infections in the United States.1,2 In healthy persons, carriage of Candida albicans is estimated at 30%-60%. 3 However, Candida species can also act as opportunistic pathogens that are capable of infecting a broad range of body
sites, especially when host resistance mechanisms are compromised. Candidemia, when Candida gains access to the
bloodstream, is a life-threatening condition, with mortality
1

2

gastrointestinal tract during surgery, breakdown of the gut
epithelial barrier occurs, which can lead to the translocation
of enteric organisms from the recipient or donor bowel into
the bloodstream or peritoneum.
Small bowel transplantation is considered a last-resort
treatment option for pediatric patients with extreme short
bowel syndrome or those suffering life-threatening complications from parenteral nutrition. Bloodstream infections are
common complications following intestinal transplant and
represent a major cause of morbidity and mortality among
SBT recipients, with up to 70% of pediatric SBT recipients
developing bloodstream infections.8 In particular, pediatric SBT recipients experience an increased incidence of candidemia, with up to 25% of recipients developing candidemia—the most common fungal bloodstream infection in
this population.9
Strains implicated in candidemia may be of endogenous or
exogenous origin.10 The donor and remnant recipient bowel
may each harbor commensal fungi,6 and donor organs may
additionally become infected during hospitalization of the donor or during procurement and preservation of the organ.10,11
There is increasing evidence for Candida infections originating
from the hospital environment and personnel, contaminated
implanted medical devices, or from the skin.12-14 The ability of
Candida to produce biofilms on catheter instruments is a common source of candidemia episodes, as these give the yeast
direct access into the bloodstream upon insertion.15
Antifungal prophylaxis is commonly administered in the
first weeks after surgery in SBT recipients. However, extensive
use of antifungal prophylaxis can select for resistant Candida
strains. For instance the recent clinical emergence of azoleresistant species (Candida glabrata and Candida krusei) is
likely due to widespread use of fluconazole and other antifungal agents.16 In addition, an overall shift towards nonC. albicans species commonly associated with fungemia has
been observed,17 possibly related to the extensive use of antifungal prophylaxis.
In the present work, we defined the gut mycobiota of SBT
recipients and genotyped ileum and bloodstream Candida isolates in attempt to infer the source of infection, and determine
the distribution of isolates within and between patients. Isolates were also assessed for antifungal susceptibility. Overall,
the data obtained in this study will contribute to the knowledge base of Candida epidemiology and infections acquired
by SBT recipients and will also help design future studies.
2 Materials and methods
Seven pediatric short bowel syndrome patients who underwent SBT and later developed candidemia at the University
of Nebraska Medical Center (UNMC) were included in this
study. The patient cohort comprised three females and four
males with a mean age of 23.1 months (median: 20 months;
range: 16-37 months). UNMC is a premier facility for SBT,
conducting approximately 20 transplants per year. Ileostomy
and blood samples (Table 1) were collected from recipients
under UNMC Institutional Review Board protocol #417-02,
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and informed consent was received from the caregivers of all
patients. Candidemia was diagnosed on the basis of at least
one sample isolated in pure culture from the blood, which
was then identified by the API 20 C test (BioMérieux, Marcy
l’Etoile, France). Multiple ileostomy samples were collected
post-transplant during hospitalization from each patient and
stored at −80°C until processing.
To obtain pure culture isolates from ileostomy samples,
approximately 250 μL of ileal effluent was grown at 37°C in
liquid media (yeast nitrogen broth [YNB; 6.7 g/L yeast nitrogen base, 10 g/L glucose, 0.76 g/L l-asparagine, 50 mg/L
chloramphenicol, 20 mg/L gentamicin sulfate], and yeast extract peptone dextrose broth [YPD; 10 g/L yeast extract, 20
g/L peptone, 20 g/L glucose, 50 mg/L chloramphenicol, pH
5.6]) to restore cells that may have been damaged by up to
10 years storage at −80°C with possible exposure to freezethaw cycles and to increase the volume available for plating.
Volumes of 100 μL were plated after 24, 48 and 72 hours
on YPD agar (supplemented with 50 mg/L chloramphenicol), CHROMagar Candida (Paris, France), potato dextrose
agar (PDA, Oxoid; supplemented with 50 mg/L chloramphenicol) and dichloran rose bengal chloramphenicol agar (DRBC;
10 g/L glucose, 5 g/L peptone, 1 g/L monopotassium phosphate, 0.5 g/L magnesium sulfate, rose bengal 0.025 g/L, dichloran 0.002 g/L chloramphenicol 0.10 g/L). Multiple liquid
and solid media were used to maximize the chances of isolating fungi. Plates were incubated at 37°C and monitored daily
for 2 weeks. Multiple colonies from each plate were further
isolated on the basis of color and morphology.
DNA was extracted from yeast cultures following the
methods of Harju et al.18 DNA from each ileostomy sample and pure culture isolate was selectively amplified by PCR
using fungal‐specific primers ITS1-F and ITS4 as described
in Suhr et al.19 To survey the gut mycobiota, DNA was extracted directly from ileostomy effluent following the protocol of Oh et al.20
PCR products from ileostomy effluent were cloned using
the pGEM®-T Easy Vector System Kit (Promega, Lyon, France)
following the manufacturer’s instructions. For each sample,
25 colonies negative for β-galactosidase activity were evaluated and those with distinct EcoR1 patterns were sequenced
on an ABI 3730xl platform at Michigan State University’s Research Technology Support Facility (East Lansing, MI, USA).
Fungal sequences were identified by sequence homology using nucleotide BLAST against the UNITE curated fungal ITS
sequence database21 and the curated FUNCBS database, as
accessed through the Centraalbureau voor Schimmelcultures
(http://www.cbs.knaw.nl/Collections/BioloMICSSequences.
aspx?file=all ; accessed September 2014). Sequences were
deposited as GenBank accessions #KU987836-KU987907.
All C. albicans and C. glabrata ileostomy and bloodstream
isolates were typed by MLST as described previously.22,23 After amplification of each fragment, PCR products were purified using the Wizard SV Gel and PCR Clean-up Kit (Promega, Madison, WI, USA). Subsequently, amplicons were
sequenced in both directions using the same primers used
for PCR. Sequences were aligned and assembled using

Candida infection in pediatric small bowel transplant recipients

3

Table 1. Outline of patients, sample collection, species identification, RAPD and MLST genotypes

Patient

Age at
transplant			
(mo)
Sex
Samplea

Days
posttransplant

Ileal
Candidab

Ileal fungi
(non-Candida)

Blood
isolate

RAPD
genotypec

MLST
genotype

P32
28
F
			

32_I_1
32_B_1

390
CA
Acr, EN, PR
400 			

CPd

G

n/a

P33
37
F
			
			
			

33_I_1
33_I_2
33_B_1
33_I_3

532
CA, CK
PR
579
CAd, CK 			
587 			
CAd
755
CA, CG, CKd, CTd

A
A

2854
2854

P39
23
M
			
			

39_I_1
39_B_1
39_I_2

64
CGd 			
187 			
CGd
201
CGd 			

D
D
D

3
3
3

P47
20
F
			
			
			
			
			
			
			
			
			
			

47_I_1
47_I_2
47_I_3
47_B_1
47_I_4
47_I_5
47_B_2
47_I_6
47_I_7
47_I_8
47_I_9

12 		
EN, PR
23
CP
Deb, PR, Tri
27
CGd, CP 			
29 			
CPd
30
CGd, CPd
PR 		
34
CGd, CP
PR 		
35 			
CPd
41
CG
48
CGd 			
56
CG
61
CGd, CP 			

E
H
CG-E, CP-G
E
H

2
n/a
CG-2, CP-n/a
2
n/a

E

2

E

2

P62
16
M
			
			
			
			
			

62_I_1
62_I_2
62_B_1
62_I_3
62_I_4
62_I_5

53 		
PR
61
CA
Fus, PR
69 			
WAd
72
CA, CT
Deb, Fus, PF, PR
103
CA, CPd 			
138
CA PR

n/a

n/a

G

n/a

P74
20
M
			
			
			
			
			
			
			

74_I_1
74_I_2
74_B_1
74_I_3
74_I_4
74_B_2
74_I_5
74_I_6

254
CA
PR
274 		
PR
282 			
357
CA, CL
381
CA
EN, PR
392 			
400 		
AP
402 		
SC

CPd

G

n/a

CAd

B

2855

P88
18
M
			
			

88_B_1
88_I_1
88_I_2

188 			
189 		
PR
201
CK
EN, PR, SC

COd

a. Sample name given as patient number_ileostomy (I) or bloodstream (B)_sample number.
b. CA, Candida albicans; CG, C. glabrata; CK, C. krusei; CL, C. lusitaniae; CO, C. orthopsilosis; CP, C. parapsilosis; CT, C. tropicalis; Acr, Acremonium;
Deb, Debaryomyces; Fus, Fusarium; Tri, Trichoderma; AP, Aureobasidium pullulans; EN, Epicoccum nigrum; PF, Pichia fermentens; PR, Penicillium cf.
roqueforti; SC, Saccharomyces cerevisiae; WA, Wickerhamomyces anomalus.
c. RAPD and MLST genotypes are given for samples in pure cultured only, and are described in the text. Candida parapsilosis lacks an MLST, and W.
anomalus lacks MLST and RAPD, systems.
d. Obtained in culture.

ClustalW implemented in BioEdit Sequence Alignment Editor version 7.3.2. For C. albicans, heterozygosities were assessed by visual inspection of the chromatograms and designated using IUPAC nomenclature. Sequences were entered

into the respective MLST database (http://pubmlst.org/calbicans/ & http://cglabrata.mlst.net/), and assigned an allele
profile for each locus which produced a sequence type (ST)
based on the entire allelic combination

4

Candida albicans, C. glabrata and Candida parapsilosis
isolates were also typed by RAPD using the primer Oligo
2 (5′-TCACGATGCA- 3′) as described previously.24 Candida
parapsilosis isolates were further typed with the primer OPE04 (5′-GTGACATG-3′). 25 Amplification reactions were as described above for PCR except 10 ng of DNA was used. Amplicons were separated in a 1.5% agarose gel for 90 minutes
and visualized.
Antifungal susceptibility was assessed using the Sensititre
YeastOne YO-9 plate (TREK Diagnostic Systems, Cleveland,
OH, USA), which provides antifungal susceptibility testing
and minimum inhibitory concentration (MIC) determination against nine antifungals (see Table 2, below), following the manufacturer’s instructions. Guidelines for breakpoint interpretations for amphotericin B were determined
from CLSI M27-A26; for anidulafungin, caspofungin, fluconazole, micafungin and voriconazole from CLSI M27-S4;27 for
5-flucytosine and itraconazole from CLSI M27-S3,28 and for
posaconazole from the European Committee on Antimicrobial Susceptibility Testing.29
3 Results
The ileal effluent of SBT recipients harbored several fungal species (Table 1). Candida albicans was the predominant species,
detected in the ileum of four patients (57%) and 11 out of 28
ileostomy samples (40%). All ileum samples tested contained
detectable fungi, and the species detected per sample ranged
from 1 to 6. P33 harbored four Candida species in a single ileal
sample. Other, non-Candida fungi were also detected in 60%
of ileal samples, with Penicillium roqueforti and/or allied species (Penicillium roqueforti, Penicillium carneum and Penicillium paneum cannot reliably be distinguished on the basis of
ITS sequence) detected in samples for all patients.
Species isolated from each blood culture are shown in Table 1. All bloodstream infections were caused by Candida.
Candida parapsilosis was the predominant species isolated
from the bloodstream (three patients). Candida albicans was
the second most-isolated species from the bloodstream, in
two patients, whereas C. glabrata, C. orthopsilosis and C. pelliculosa (=C. beverwijkiae Wickerhamomyces anomalus) were
each isolated from one patient. P74 sustained two distinct
bloodstream infections, from C. parapsilosis in July 2006 and
from C. albicans in November of 2006.
All C. albicans (n = 3) and C. glabrata (n = 8) isolated in
culture from the ileum and bloodstream were subjected to
MLST. Twelve alleles were identified among the seven loci of
C. albicans isolates, including two new alleles, which generated a new, unique diploid sequence type (Table S1). Fourteen polymorphic nucleotide sites were found between the
two C. albicans sequence types. Both C. albicans sequence
types detected in this study (ST 2854 & ST 2855) are novel
isolates and have been deposited in the MLST database. In
addition, two sequence types (ST 2 & ST 3), consisting of
12 alleles and 23 variable nucleotide sites, were identified
among the six loci of C. glabrata isolates (Table S1).
For P33, ileostomy and blood C. albicans isolates yielded
one sequence type (ST 2854). Candida albicans causing
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bloodstream infection in P74 was ST 2855, distinct from
P33. Candida glabrata ileostomy and bloodstream isolates
from P39 shared ST 3. P47, who developed candidemia by C.
parapsilosis, had gastrointestinal colonization by C. glabrata.
However, the C. glabrata isolated from this individual was ST
2, which was a distinct genotype from P39. In both species
for which MLST was possible, sequence type was consistent
within a patient over time, but differed between patients.
RAPD fingerprinting with primer Oligo 2 was performed
on all cultured Candida isolates that were detected more than
once (see Table 1; Figures S2-S4). Four C. albicans isolates generated three distinct RAPD profiles. Candida albicans isolates
recovered from the ileostomy and bloodstream of P33 had the
same RAPD profile A. The bloodstream isolate from P74 gave a
distinct RAPD profile B (C. albicans was detected in ileostomy
samples from P74 but could not be cultured). The common
laboratory strain C. albicans SC5314 also gave a distinct pattern C. Nine C. glabrata isolates generated three distinct RAPD
profiles. Candida glabrata isolates obtained from the ileostomy
and bloodstream of P39 had the same RAPD profile D. Candida glabrata ileostomy isolates from five consecutive ileostomy samples over a 1 month period in P47 generated RAPD
profile E, whereas control strain C. glabrata NRRL Y-65 gave a
distinct RAPD pattern F. The RAPD results obtained from C. albicans and C. glabrata isolates are congruent with strain typing data by MLST (Table 1). No RAPD patterns for C. albicans
or C. glabrata were shared across individuals.
Seven C. parapsilosis isolates generated two distinct RAPD
profiles. Candida parapsilosis isolates from P47 showed distinct RAPD patterns between the ileum and bloodstream. The
two C. parapsilosis blood culture isolates were collected from
this patient before and after the ileostomy sample was collected. Both blood cultures generated the same RAPD pattern
H. However, the ileostomy isolate showed RAPD pattern G.
The two ileostomy samples prior to the first bloodstream collection harbored C. parapsilosis, but viable organisms could
not be cultured; therefore, RAPD could not be used to identify the C. parapsilosis to strain. Three C. parapsilosis isolates,
collected from the ileum of P62 and the blood of P32 and
P74, gave the same RAPD pattern G. Control C. parapsilosis
232, isolated from cheese, also had RAPD pattern G. Since
a C. parapsilosis MLST scheme does not exist, primer OPE04 was also used for RAPD to confirm results obtained by
primer Oligo 2. Primer OPE-04 also yielded two distinct patterns among the seven isolates, which agreed with the results
from Oligo 2 RAPD (Figure S5).
The chronological carriage of Candida strains is shown in
Figure 1. At two points, samples were collected from multiple
patients during the same time period. In both cases, patients
carried distinct strains from one another. Candida parapsilosis
isolates of RAPD profile G were detected consistently over time
in four patients. Isolates of all other MLST and RAPD profiles
were each restricted to a single patient in the tested samples.
No one genotype dominated the patient population.
The antifungal susceptibilities and MICs for the yeast isolates against nine antifungals are shown in Table 2. Candida
glabrata isolate 39_B_1 was reported as susceptible dose-dependent to fluconazole (which was administered in a level to

S

S

R

R

S

S

R

S

S

SP

0.015

1

2

2

2

1

0.06

0.03

0.03

MIC

S

S

S

S

S

S

S

S

S
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ANDc		

0.015

0.25

2

2

0.25

0.5

0.25

0.03

0.03

MIC

S

S

S

S

S

S

I

S

S
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CASc		

<0.06

0.06

0.12

0.12

0.25

0.12

<0.06

0.12

0.12

MIC

S

S

S

S

S

S

S

S

S

SP

FCTd		

2

1

2

2

1

1

32

4

0.5

MIC

S

S

S

S

S

S

SDD

SDD

S

SP

0.06

0.06

0.06

0.06

0.12

0.12

2

0.12

0.06

MIC

S

S

S

S

S

S

R

S

S

SP
S

SP

0.015

1

2

2

1

0.5

0.015

S

S

S

S

S

S

S

<0.008 S

0.008

MIC

FLZc		ITZd		MCFc		

0.12

0.03

0.06

0.06

0.06

0.12

2

0.06

0.03

MIC

S

S

S

S

S

S

R

S

S

SP

POZe		

0.06

0.12

0.06

0.06

0.03

0.12

2

0.12

0.03

MIC

VORc

S

S

S

S

S

S

NDf

S

S

SP

Abbreviations: AMB, amphotericin B; AND, anidulafungin; CAS, caspofungin; FCT, 5-flucytosine; FLZ, fluconazole; ITZ, itraconazole; MCF, micafungin; POZ, posaconazole; VOR, voriconazole; MIC,
minimum inhibitory concentration; SP, susceptibility profile, S, susceptible; SDD, susceptible dose-dependent; I, intermediate; R, resistant; ND, not determined.
a. Antifungal susceptibility determined using the Sensitire®YeastOne plate (TREK Diagnostic Systems, Cleveland, OH, USA).
b. The methodology to currently determine amphotericin B MICs for Candida species is inconsistent and present interpretation suggests that an MIC of >1 μg/mL is likely to be resistant.26
c. Guidelines for breakpoint interpretations for anidulafungin, caspofungin, fluconazole, micafungin and voriconazole are determined from CLSI M27-S4.27
d. Guidelines for breakpoint interpretations for 5-flucytosine and itraconazole are determined from CLSI M27-S3.28
e. Antifungal breakpoints used for posaconazole are those described by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for Candida species.29
f. Current data are insufficient to demonstrate a correlation between in vitro susceptibility testing and clinical outcome for C. glabrata and voriconazole.27
g. The teleomorphic state of C. pelliculosa is identified as Wickerhamomyces anomalus (Pichia anomala).

62_B_1

0.5

>1

0.25

47_B_2

74_B_1

Candida pelliculosag

1

>1

32_B_1

1

>1

47_B_1

Candida parapsilosis

88_B_1

Candida orthopsilosis

39_B_1

Candida glabrata

1

1

33_B_1

MIC

74_B_2

Candida albicans

Candida species

AMBb		

MIC (μg/mL) and susceptibility profile

Table 2. Summary of MIC values and antifungal susceptibility of bloodstream isolatesa
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Figure 1. Chronological outline of patient sample collection. The MLST sequence types and RAPD profiles are indicated for each patient

patient considered susceptible), intermediate to caspofungin,
and resistant to amphotericin B, itrazonazole and posaconazole. Candida parapsilosis isolates 47_B_1 and 47_B_2 were
determined to be resistant to amphotericin B. Candida albicans, C. orthopsilosis and C. pelliculosa isolates were uniformly
susceptible or susceptible dose dependent (74_B_2 for fluconazole) to all antifungals. In addition, we tested one ileal isolate
of C. krusei (from 33_I_3; not shown). This isolate was resistant
to fluconazole, showed an intermediate response to 5-flucytosine, and was susceptible dose-dependent to itraconazole.
Isolates showed a wide range of MICs to fluconazole (0.5-32
μg/mL), as well as micafungin (<0.008-2 μg/mL), anidulafungin (0.015-2 μg/mL) and caspofungin (0.015-2 μg/mL), and a
narrow range for 5-flucytosine (<0.06-0.25 μg/mL).
4 Discussion
This study describes SBT recipients who developed fungemia post-transplant at the UNMC from 2004 to 2007. We
employed a variety of techniques to identify and characterize
Candida isolates colonizing and infecting SBT recipients. This
is the first study characterizing the fungal intestinal microbiota of SBT recipients. Comprehensive surveys of gut fungi, using next-generation sequencing methods, may report dozens
of species or OTUs (operational taxonomic units) from a single fecal sample30; however, the majority of these are rarely
detected environmental or dietary fungi that do not appear
to colonize the gastrointestinal tract.31 The fungi we detected
from ileostomy samples in this study are largely those species that do have a well-established association with and role
in the gut, especially Candida species.
Prior to 1990, the predominant species causing Candida
infections was C. albicans.32 In recent years infections caused
by non-albicans species have increased in clinical importance.17 Bloodstream infections in our study were most frequently caused by C. parapsilosis (four cases), whereas C.
albicans was isolated in only two infections. Only P47 experienced candidemia shortly after transplant (at 29 and 35 days,
with C. parapsilosis), accordingly, this is the only patient for

whom the 2 week postoperative antifungal prophylaxis with
fluconazole was anticipated to influence species isolated or
susceptibility. One infection each was caused by C. glabrata,
C. orthopsilosis and C. pelliculosa.
Candida pelliculosa is widespread in the environment and
in food, and is an opportunistic human and animal pathogen. This yeast transiently colonizes the oropharyngeal and
gastrointestinal tract of humans and it has been implicated
in outbreaks in neonatal and pediatric intensive care units.33
Candida pelliculosa was not identified in the intestine of P62
from whom it was isolated from the blood. Therefore, it is
possible that this patient acquired this species from an exogenous source, as suspected in previous cases.34
We detected previous digestive tract colonization with
Candida in six of the patients with candidemia. Our findings
suggest that at least two bloodstream infections (in P33 and
P39) originated from Candida colonizing the small bowel, although complete exclusion of environmental exposure during hospitalization is not possible at this time. Closely related isolates in the intestine and blood have been reported
in other studies.35,36 Gastrointestinal colonization is an important source of candidemia, although only a few studies using
molecular typing methods have been reported and sample
numbers are small.14 Many studies only report an association between anatomic site of Candida colonization as a risk
factor for subsequent candidemia and invasive candidiasis in
hospitalized and critically ill patients.37,38 However, it is plausible that patients in our study would be infected by endogenous Candida due to the invasive nature of this procedure.
P47 had different strains of C. parapsilosis colonizing the
intestine and infecting the bloodstream, suggesting candidemia derived from a distinct source. Candida parapsilosis has been reported in the human oral microbiota so endogenous infection remains a possibility. Other possibilities
include mutation within the patient and increase in prevalence of a previously undetectable isolate. Nucleotide sequence variation among serial isolates or as separate clones
from individual patients is a known phenomenon for strains
of C. albicans.39 The majority of documented C. parapsilosis
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infections are of exogenous origin; endogenous infections
are rarely seen.36 Candida parapsilosis is the most common
fungus recovered from the hands and studies have implicated health care workers’ hands as the source of nosocomial candidaemia.40 Another possible route of C. parapsilosis transmission could be contaminated parenteral nutrition
and intravascular devices.41 Candida parapsilosis was not detected in ileostomy samples from P32 and P74, who developed bloodstream infection with C. parapsilosis. These two
individuals could represent further cases of exogenous acquisition. In addition to P88, who had no gastrointestinal colonization with the fungus isolated from the bloodstream, C.
orthopsilosis, may have acquired candidemia exogenously.
P74 was co-infected by two Candida species. Candida
parapsilosis was the first organism recovered from the blood,
but this was not detected in ileostomy samples prior to infection. Candida albicans was present in three ileostomy samples
prior to C. albicans detection in the blood. The possibility exists that P74 was infected exogenously by C. parapsilosis and
endogenously by the patient’s own intestinal C. albicans. The
inability to culture C. albicans from the patient’s ileum precluded strain typing and thus confirmation of a possible endogenous source.
Studies have documented the ability of Candida isolates to
persist in hospital settings and cause temporally associated
infections.42,43 In our study, temporal analysis revealed multiple species were responsible for causing bloodstream infections during the study period. At two different time points,
samples collected from two patients overlapped, but the patients did not carry the same genotype. However, the same
C. parapsilosis genotype G in four patients was documented
at multiple time points. Therefore, there is potential evidence
that this C. parapsilosis strain had a common source. However, environmental sampling would be necessary to confirm
or rule out any exogenous source.
Methods used to strain-type Candida species have greatly
advanced our knowledge of fungal epidemiology and MLST
has been shown to be more discriminating than RAPD for
C. albicans.44 In our study, MLST detected distinct sequence
types between, but not within, patients. This suggests independent, endogenous acquisition of C. albicans candidemia,
but would need to be confirmed by full genome sequencing.
RAPD patterns yielded the same conclusions as MLST for C.
albicans and C. glabrata isolates. RAPD fingerprints generated by two independent primers gave the same results for
C. parapsilosis isolates. Other RAPD primers may possibly further differentiate between our isolates; conversely, genetic
variation in C. parapsilosis may be minimal. Other methods
such as microsatellite markers may be more discriminatory
for epidemiological investigations of C. parapsilosis,45 but ultimately future work will have to encompass full genome sequence of well-documented, larger collections.
There is increasing concern regarding antifungal resistance in Candida, especially C. parapsilosis. In our study, two
C. parapsilosis isolates from the same patient showed resistance to amphotericin B. In addition, the one isolate of C. glabrata also showed resistance to amphotericin B using the in
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vitro microplate susceptibility testing method. Although resistance of Candida species to amphotericin B is rare, the frequency of resistance to amphotericin B has been shown to be
highest with C. parapsilosis (2.5%) followed by C. krusei (2.0%)
and C. glabrata (0.8%).46 Interestingly also, the formation of
biofilms in C. parapsilosis did lead to a significant (P = .0004)
lowering of activity for amphotericin B from 100% susceptible to 32.1% susceptible in this species.47 However, there are
no standardized methods available to perform and interpret
in vitro amphotericin B susceptibility testing.26 Candida albicans isolates from this study were susceptible to all antifungal agents. The C. glabrata strain causing candidemia in addition to amphotericin B was also resistant to itraconazole and
posaconazole, intermediate to caspofungin and susceptible
dose-dependent to fluconazole. This strain was also detected
in the patient’s ileal fluid 4 months prior to infection. One other
patient harbored C. glabrata in the ileum, but was only infected
by C. parapsilosis. The one C. krusei isolate we obtained in culture showed some level of drug resistance, notably to fluconazole; however, no C. krusei strain in this study was implicated
in candidemia. All patients were exposed to fluconazole prophylaxis in the immediate perioperative period.
One limitation of this study was the inability to culture viable organisms from several ileostomy samples. Thus, while
we know an ileostomy sample harbored a specific species,
intestinal origin could not be confirmed due to the inability to strain-type. Techniques to strain-type species in mixed
matrices need to be developed to avoid requiring pure cultures of isolates. Another limitation was the inability to determine whether ileal Candida originated in the donor or recipient bowel. Donor-derived Candida infections have been
documented in kidney transplant recipients.48 To date, no
efforts have been made to identify Candida species and/or
strains from the donor small bowel, or from other sources of
recipient microbiota, to investigate the origin of candidemia
in SBT recipients.
These findings highlight the possibility of hospitalized SBT
patients acquiring candidemia both endogenously and exogenously, although the exact route of infection in these transplant patients is not clear. Knowing the source of Candida implicated in infection (recipient, donor or hospital acquired)
will inform pretransplant interventions and treatments to improve outcomes for SBT patients. Future efforts should include collection and culturing of donor and recipient samples
(including oral, colon and skin microbiota) prior to transplant,
as well as continuing ileostomy sample collection throughout hospitalization. This would highlight the role (if any) of
the donor microbiota and may direct prevention efforts. Targeted interventions could reduce exogenous and endogenous infections, and environmental sampling may reveal
sources of infection and solutions. Reducing endogenous recipient-derived infection by means of existing prophylactics
will be more difficult and will require innovative interventions.
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Additional Supporting Information follows.

Supplemental Figure S1. RAPD fingerprint patterns of C. albicans isolates obtained
with primer Oligo 2. Fingerprints indicated with the same letter have equal genotypes.
First lane 1 KB+ molecular size marker. Laboratory strain C. albicans SC5314 included
with isolates.

Supplemental Figure S2. RAPD fingerprint patterns of C. glabrata isolates obtained
with primer Oligo 2. Fingerprints indicated with the same letter have equal genotypes.
First lane 1 KB+ molecular size marker. C. glabrata NRRL Y-65 included with isolates.

Supplemental Figure S3. RAPD fingerprint patterns of C. parapsilosis isolates
obtained with primer Oligo 2. Fingerprints indicated with the same letter have equal
genotypes. First lane 1 KB+ molecular size marker. C. parapsilosis 232 included with
isolates.

Supplemental Figure S4. RAPD fingerprint patterns of C. parapsilosis isolates
obtained with primer OPE-04. Fingerprints indicated with the same shape have equal
genotypes. First lane 1 KB+ molecular size marker. C. parapsilosis 232 included with
isolates.

Supplemental Table S1. MLST genotypes of the C. albicans and C. glabrata isolates
studied.
Candida albicans
Allele number
AAT1a

ACC1

ADP1

MPIb

SYA1

VPS13

ZWF1b

MLST
Genotype

33_I_2

156

4

4

4

204

4

4

2854

33_B_1

156

4

4

4

204

4

4

2854

74_B_2

35

7

6

4

4

4

239

2855

Sample

Candida glabrata
Allele number
FKS

LEU2

NMT1

TRP1

UGP1

URA3

MLST
Genotype

39_I_1

5

7

8

7

3

6

3

39_B_1

5

7

8

7

3

6

3

39_I_2

5

7

8

7

3

6

3

47_I_3

1

2

2

1

1

1

2

47_I_4

1

2

2

1

1

1

2

47_I_5

1

2

2

1

1

1

2

47_I_7

1

2

2

1

1

1

2

47_I_9

1

2

2

1

1

1

2

Sample

